JUN 10, 2019 10:01 AM PDT

Novel Treatments for Auto-immune Disorders

WRITTEN BY: Nouran Amin

A recent research study examined a library of almost 300,000 small molecules to search for a molecule that may be a potential target for the human GMP-AMP synthase (cGAS)—an enzyme that can detect and bind to cytosolic DNA and initiating a chain reaction leading to immune activation with the result of the destruction of the DNA-shedding pathogen.

Through their initial screening, researchers were able to identify two molecules that showed some activity against cGAS.

“The hits from library compounds were a great starting point, but they were not potent enough,” said postdoctoral associate Lodoe Lama. “So we used them as molecular scaffolds on which to make improvements, altering their structures in ways that would increase potency and also reduce toxicity.”

In collaboration with Tri-Institutional Therapeutics Discovery Institute, scientists created three compounds that inhibited cGAS activity in human cells. Further analytical studies by researchers at Memorial Sloan Kettering Cancer Centre showed that compounds block cGAS activation by wedging into a critical pocket.

The significance of inhibiting cGAS would be of critical therapeutic relevance to those with autoimmune diseases who have few treatment options. Currently, compounds are being optimized for prospective use in patients particularly those diagnosed with a rare genetic disease called Aicardi-Goutières syndrome. Individuals with Aicardi-Goutières syndrome have an abnormal accumulation of cytosolic DNA that activates cGAS and can lead to serious neurological problems.

“This class of drug could potentially also be used to treat more common diseases, such as systemic lupus erythematosus, and possibly neurodegenerative diseases that include inflammatory contributions, such as Parkinson’s disease,” adds Thomas Tuschl, Ph.D.

Findings of the study, as reported in Nature Communications, sheds light on the causes of autoimmunity.

“Scientists will now have simple means by which to inhibit cGAS in human cells,” concluded Lama. “And that could be immensely useful for studying and understanding the mechanisms that lead to autoimmune responses.”

Source: Drug Target Review

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Injectable Implant Drug Shows Promise for HIV Treatment
In a study published in Nature Communications, alternative treatment was shown to have promising results for HIV as opposed to a daily pill regimen. Scient...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
DEC 12, 2019
Neuroscience
DEC 12, 2019
Suicidal Mitochondria Responsible for ALS
Scientists at Northwestern University have dicovered a new mechanism in the brain that may be responsable for the early stages of neurodegeneration seen in...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
DEC 12, 2019
Technology
DEC 12, 2019
Can artificial intelligence increase tuberculosis drug development?
It’s no secret that there is a shortage of tuberculosis drug development. To combat this issue, researchers at the University of Michigan designed a ...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
New Injection that Treats Peanut Allergy
Peanut allergies affect between 1 and 3% of the US population. Associated with a heightened risk of severe anaphylactic reactions, oral immunotherapy is th...
Loading Comments...